M. Bektas1, N. Koca1, E. Ozguz2, B. Ince1, Y. Yalcinkaya1, B. Artim-Esen1, M. Inanc1, M. L. Ocak1, A. Gul1. 1Istanbul Faculty of Medicine, Internal Medicine, Rheumatology Division, Istanbul, Turkey; 2Istanbul Faculty of Medicine, Internal Medicine, Rheumatology Division, Istanbul, Turkey

Background: AA amyloidosis has been associated with uncontrolled chronic inflammatory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), inflammatory bowel disease (IBD) and hereditary periodic fever syndromes, and the most common cause is familial Mediterranean fever (FMF) in Turkey.

Objectives: We herein aimed to evaluate clinical and laboratory characteristics and treatment responses of patients with AA amyloidosis retrospectively in a tertiary referral center.

Methods: Study group was consisting of patients with biopsy proven AA amyloidosis, and their data were recorded from their charts. Treatment responses were categorized as follows: complete response was defined as no increase in serum creatinine and a proteinuria below 1g/day; partial response as 50% decrease in proteinuria; and stable disease as no significant change in serum creatinine and proteinuria. Progressive disease was defined as increase in serum creatinine and/or proteinuria under treatment.

Results: 173 patients were identified, and 10 patients with no biopsy result and/or missing data were excluded. A total of 163 patients (79 females, 84 males) were included in the study. Median age of patients was 54.4, and median age at diagnosis of amyloidosis was 33.5. Most common cause of amyloidosis was FMF (78.5%), followed by idiopathic cases (21.7%) and patients with AS (4.4%). A quarter (26%) of amyloidosis patients had a family history for AA amyloidosis, and 59% of patients with FMF had a family history of FMF. Amyloidosis was confirmed by renal biopsy in 76.1%, by gastrointestinal (GIS) biopsy in 11.7%, and by other biopsies in the remaining. Renal involvement was documented in 160 (98.2%) patients, ESRD during the post-index period (ie the end of data availability, end of the study period) was significantly higher in patients with GFR≤60 ml/min/1.73 m² compared to patients with GFR≥60 ml/min/1.73 m² (90.6 vs 63.8%, p=0.005, Figure 1). A total of 113 (70.2%) patients used glucocorticoids at 5 mg fwm, then slow tapering of steroid doses, and their data were recorded from their charts. Treatment responses were categorized as follows: complete response was defined as no increase in serum creatinine and a proteinuria below 1g/day; partial response as 50% decrease in proteinuria; and stable disease as no significant change in serum creatinine and proteinuria. Progressive disease was defined as increase in serum creatinine and/or proteinuria under treatment.

Conclusion: Increased rate of ESRD and progression of amyloidosis findings in patients who presented with GFR<60 ml/min emphasizes the importance of early diagnosis. Although mortality rate is very high in patients with AA amyloidosis due to FMF disease, it may be possible to reduce mortality with an effective treatment.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.1402

M. Bektas1, N. Koca1, E. Ozguz2, B. Ince1, Y. Yalcinkaya1, B. Artim-Esen1, M. Inanc1, M. L. Ocak1, A. Gul1. 1Istanbul Faculty of Medicine, Internal Medicine, Rheumatology Division, Istanbul, Turkey; 2Istanbul Faculty of Medicine, Internal Medicine, Rheumatology Division, Istanbul, Turkey

Background: AA amyloidosis has been associated with uncontrolled chronic inflammatory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), inflammatory bowel disease (IBD) and hereditary periodic fever syndromes, and the most common cause is familial Mediterranean fever (FMF) in Turkey.

Objectives: We herein aimed to evaluate clinical and laboratory characteristics and treatment responses of patients with AA amyloidosis retrospectively in a tertiary referral center.

Methods: Study group was consisting of patients with biopsy proven AA amyloidosis, and their data were recorded from their charts. Treatment responses were categorized as follows: complete response was defined as no increase in serum creatinine and a proteinuria below 1g/day; partial response as 50% decrease in proteinuria; and stable disease as no significant change in serum creatinine and proteinuria. Progressive disease was defined as increase in serum creatinine and/or proteinuria under treatment.

Results: 173 patients were identified, and 10 patients with no biopsy result and/or missing data were excluded. A total of 163 patients (79 females, 84 males) were included in the study. Median age of patients was 54.4, and median age at diagnosis of amyloidosis was 33.5. Most common cause of amyloidosis was FMF (78.5%), followed by idiopathic cases (21.7%) and patients with AS (4.4%). A quarter (26%) of amyloidosis patients had a family history for AA amyloidosis, and 59% of patients with FMF had a family history of FMF. Amyloidosis was confirmed by renal biopsy in 76.1%, by gastrointestinal (GIS) biopsy in 11.7%, and by other biopsies in the remaining. Renal involvement was documented in 160 (98.2%) patients, ESRD during the post-index period (ie the end of data availability, end of the study period) was significantly higher in patients with GFR≤60 ml/min/1.73 m² compared to patients with GFR≥60 ml/min/1.73 m² (90.6 vs 63.8%, p=0.005, Figure 1). A total of 113 (70.2%) patients used glucocorticoids at 5 mg fwm, then slow tapering of steroid doses, and their data were recorded from their charts. Treatment responses were categorized as follows: complete response was defined as no increase in serum creatinine and a proteinuria below 1g/day; partial response as 50% decrease in proteinuria; and stable disease as no significant change in serum creatinine and proteinuria. Progressive disease was defined as increase in serum creatinine and/or proteinuria under treatment.

Conclusion: Increased rate of ESRD and progression of amyloidosis findings in patients who presented with GFR<60 ml/min emphasizes the importance of early diagnosis. Although mortality rate is very high in patients with AA amyloidosis due to FMF disease, it may be possible to reduce mortality with an effective treatment.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.3805
the GCA cohort vs 36.3 (±10.2) days in the GnP cohort (p<0.001). Although the mean (SD) daily dose of GC (prednisone equivalent) was similar in both cohorts (276 ±28.20 vs 277 ±25.16 mg), the mean (SD) cumulative GC dose was significantly higher in the GCA cohort than the GnP cohort (3503.0 ±4622.6 mg vs 5037.7 ±15935.51 mg; p<0.001). This indicates that GCA pts had chronic GC exposure over the study period while GnP pts likely utilized higher dose GC burst therapy less frequently. The number of incident complications associated with GC use were significantly greater in the GCA cohort, and included hypertension, diabetes, skin toxicity, infections, neurotoxic effects, gastrointestinal complications, ocular effects, and cardiovascular disease (p<0.05).

Conclusion: The overall GC burden in pts with GCA is significantly higher than the general population and may result in downstream complications related to GC exposure. The incidence of GC-related complications was statistically significantly higher in GCA pts compared with GnP pts, even with a short duration of GC use. The early onset of these complications may be a significant contributor to long-term healthcare costs in GCA pts.

Acknowledgments: Study and medical writing (provided by Gauri Saal, MA, Economics, Prime, Knutsford, UK, under the direction of authors) were funded by Sanofi, Inc.


Background: Immune checkpoint inhibitors (ICI), such as anti-CTLA-4 and anti-PD1/PD-L1 monoclonal antibodies, have produced impressive clinical results in different types of cancer. However, immune-related adverse events (irAEs) may develop a wide spectrum of disabling syndromes. Knowledge of different rheumatic irAEs induced by ICI is increasing over the last years, however clinical patterns, time to onset of different irAEs according to treatment and follow-up are less well known.

Objectives: To describe different clinical patterns of rheumatic irAEs induced by ICI and their rheumatic and oncological outcomes.

Methods: We included consecutive patients with rheumatic irAEs from 3 different referral centers in Barcelona with special emphasis in articular irAEs. Four main clinical syndromes were identified: inflammatory arthritis (IA), non-inflammatory arthralgias (NIA), psoriatic arthritis (PsA)-like and polymyalgia (PMR)-like. We conducted a baseline visit and then follow-up in order to determine their clinical pattern, treatment response and outcome. Longitudinal visits were done from January 2017 to January 2020. Patients with other non-articular diagnosis were not included in the follow-up analysis.

Results: We included 55 patients. A total of 34 patients were male (61.8%) with a mean age of 65.0 ± 11.4 years. Oncologic underlying diagnosis was lung carcinoma in 24 (43.6%) patients, followed by melanoma in 17 (29%), urothelial cancer in 4 (7.3%), breast in 2 (3.6%) and 2 (3.6%) acute myeloid leukemia among others. Seven (12.7%) patients received ICI as combined therapy. Different ICI were used including: Pembrolizumab in 21 (38.2%), Nivolumab 13 (23.6 %), Atezolizumab 6 (10.9%), Durvalumab 5 (9.0%), Ipilimumab + nivolumab in one case. Twelve out of 12 patients had an underlying rheumatic disease before ICI treatment. Eleven patients developed other irAEs before or at the same time as rheumatic syndromes (mainly colitis and thyroiditis). Main rheumatic irAE included: IA in 23 (41.8%), NIA in 16 (29.1%), PsA-like in 6 (10.9%), PMR-like in 5 (9.1%) among others. Time from ICI to irAEs was 8.3 ± 8.4 months (mo). irAE presented earlier in patients with combined ICI therapy than in patients with monotherapy (6.6 ± 4.0 vs 8.6 ± 9.0 mo, p=NS, Figure 1A). Time (in mo) from ICI initiation to irAE onset was different according to treatments. For Nivolumab 10.0 ± 10.6, Anti TIM3 10.0 ± 14, Durvalumab 9.0 ± 2.0, Ipilimumab 7.98 ± 9.21, Pembrolizumab 7.28 ± 7.53, Atezolizumab 6.0 and Atalozizumab 4.4 ± 5.38 mo (Figure 1B). Time from ICI initiation and onset also differs among rheumatic irAEs (Figure 2). Mean time follow-up was 13.4 ± 10.9 mo. At the last visit, 45% were under GC, mean dose of 3.6 mg/d (range 0-40). DMARD were needed in 15% of patients (6 patients MTX, 1 with LEF and 1 SFZ). At the last visit, 11 (22.9%) patients remain with persistent arthritis, 25% intermittent flares and 52% had a self-limited pattern. Regarding oncologic outcome, 30.2% were on remission, 30.2% in partial response and 39.8% with tumor progression. Eleven (20%) of patients died.

Conclusion: We described different clinical patterns according treatment and irAEs. Combined ICI therapy and patients treated with Atezolizumab had earlier onset of symptoms. Vasculitis and PMR-like syndromes appear in earlier phases. After a mean follow-up of around 1 year, one-quarter of the patients remain with persistent arthritis and 15% require DMARD therapy.

Disclosure of Interests: Jose A. Gómez-Puerta Speakers bureau: Abbvie, BMS, GSK, Lilly, Pfizer, Roche, Carolina Perez-Garcia: None declared, David Lobo Prat: None declared, Roberto Gumucio: None declared, Fabiola Ojeda: None declared, Ana Milena Millán Arciniegas: None declared, Sebastian Rodríguez-Garcia: None declared, Virginia Ruiz Speakers bureau: Lilly, Pfizer, Héctor Corominas Speakers bureau: Abbvie, BMS, Lilly, Pfizer

DOI: 10.1136/annrheumdis-2020-eular.4308

Background: Vascularitis (VCS) is a novel high potency calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for therapeutic drug monitoring. LN occurs more frequently and is more severe in Hispanic/Latino ethnicity (SLE) patients. The recently completed phase 3 AURORA study builds on the favorable efficacy seen in the Phase Ib AURA-LV study in patients with active LN.

Objectives: Document efficacy and safety of VCS vs placebo over one year when used with 2 grams of MMF daily and a rapid steroid taper in patients with active LN.

Methods: AURORA is a Phase III multicenter, randomized, double-blind, placebo-controlled 52-week study of active LN patients. Patients were randomized 1:1 to VCS (23.7 mg BID) or placebo in combination with mycophenolate (MMF, 1 g BID) and rapidly tapered oral steroids. The primary endpoint was renal response (RR) at 52 weeks, defined as UPCR of ≤ 0.5 mg/mg, eGFR > 60 mL/min, or no confirmed decrease from baseline in eGFR of > 20%, presence of sustained, low dose steroids and no administration of rescue medication. Ethnicity subgroup analyses of RR was also undertaken given the higher severity of disease in the Hispanic/Latino LN patients.

Results: There were 357 patients enrolled, 88% female, median age of 31 and 33% of Hispanic/Latino ethnicity. Renal response by intention to